Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.57 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.57 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.57 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | RARB | P10826 | 1/20 | 0.57 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.57 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598280 | 1.00 | PTGS2 (0.61) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL1590331 | 1.00 | PTGS2 (0.61) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| Hydrochloric Acid SCHEMBL5846545 | 0.98 | PTGS2 (0.59) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL11884258 | 0.94 | PTGS2 (0.71) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| Guanidine SCHEMBL5348313 | 0.90 | PTGS2 (0.52) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL11568894 | 0.89 | PTGS2 (0.50) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL59197 | 0.88 | PTGS2 (0.74) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL15695554 | 0.86 | BRD4 (0.61) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL12225982 | 0.86 | BRD4 (0.61) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL6551674 | 0.86 | PTGS2 (0.65) | PTGS2PTGS1LMNACYP2C9AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114014825-B | Synthesis method of histamine H3 receptor antagonist telithromycin | 河南师范大学 | 2023-06-02 | — | — | CN | claimed |
| CN-114014825-A | Efficient synthesis method of histamine H3 receptor antagonist teloprolofen | 河南师范大学 | 2022-02-08 | — | — | CN | claimed |
| EP-1797083-A1 | SULFONAMIDE COMPOUNDS | Janssen Pharmaceutica, N.V. (BE) | 2007-06-20 | — | — | EP | claimed |
| WO-2006036670-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-06 | — | — | WO | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| EP-1135417-B1 | POLYSACCHARIDE CHIRAL ESTERS, ONE OF THE METHODS FOR PREPARING THEM AND THEIR USES FOR OBTAINING OPTICALLY ENRICHED ACIDS OR CHIRAL CHROMATOGRAPHY | UNIV DROIT D ECONOMIE ET DES S (FR) | 2003-06-25 | — | — | EP | claimed |
| US-5663030-A | A PHENYL OR NORBORNANE DERIVATIVE AS AN ADDITIVE TO REDUCE HEAT AND ENERGY REQUIRED TO FUSE THE TONER AND TO REDUCE JAMMING OF THE EQUIPMENT | XEROX CORPORATION (US) | 1997-09-02 | — | — | US | claimed |
| CN-122036574-A | Drug design strategy for releasing hydrogen sulfide based on enzymolysis thiocarbonyl and application of drug design strategy in modification of terminal carboxylic acid drug | 中国药科大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036588-A | Drug design strategy for releasing hydrogen sulfide based on enzymolysis thiocarbonyl and application of drug design strategy in indole mother nucleus drug modification | 中国药科大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036573-A | Drug design strategy for releasing hydrogen sulfide based on enzymolysis thiocarbonyl and application of drug design strategy in diclofenac-like drug modification | 中国药科大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| EP-4702033-A1 | DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-3704117-B1 | AZABICYCLO DERIVATIVES FOR TREATING OCULAR DISORDERS | ALCON INC (CH) | 2026-01-28 | — | — | EP | disclosed |
| US-4268442-A | REACTING AN AROMATIC ALKEHYDE WITH A TRIHALOMETHANE AND AN ALKANETHIOL IN THE PRESENCE OF A BASE AND AN APROTIC SOLVENT | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1981-05-19 | — | — | US | disclosed |
| US-4226790-A | ALKANOATE SALTS, WITH PEROXY CARBOXYLIC ACID, MANGANESE SALT | THE UPJOHN COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| EP-0011279-A1 | Process for the preparation of aromatically substituted acetic acids | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1980-05-28 | — | — | EP | disclosed |
| US-4151303-A | Phenoxyalkylcarboxylic acid compounds and serum-lipid and triglyceride depressing therapeutic compositions | BOEHRINGER MANNHEIM GMBH (DE) | 1979-04-24 | — | — | US | disclosed |
| US-4142054-A | TRIVALENT THALLIUM SALT | THE UPJOHN COMPANY (US) | 1979-02-27 | — | — | US | disclosed |
| US-4135051-A | ENOL ETHER OF AN ARYL ALKYL KETONE WITH A THALLIJM SALT, REGENERATION OF THALLIUM SALT BY ADDING PERACID AND REACTIVE METAL COMPOUND | THE UPJOHN COMPANY (US) | 1979-01-16 | — | — | US | disclosed |
| US-4107439-A | Process for preparing arylalkanoic acid derivatives | THE UPJOHN COMPANY (US) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | STS, NR5A1, CYP21A2 | PTGS2 1705/4885PTGS1 618/4885LMNA 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.